FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a method of treating Willebrand disease, including the introduction of recombinant Willebrand factor (rWF) and recombinant FVIII (rFVIII), where rWF is a composition of high molecular weight multimers of WF, containing at least 40 % of WF decamers or higher order multimers, where rWF ripens in vitro when processed by furin, where the ratio of pro-coagulating activity of FVIII (ME FVIII:K) to ristocetin-cofactor activity of rWF (ME rWF:RCo), which is administered to a subject, ranges from 2:1 to 1:4 and where rWF and rFVIII are administered together in the primary dose, and then the subsequent reapplication is carried out with rWF alone. Group of inventions also relates to the use of a composition containing rWF and rFVIII, as described above, for the treatment of von Willebrand disease.
EFFECT: group of inventions provides an increase in the half-life of FVIII and due to this improved treatment of Willebrand disease.
16 cl, 5 ex, 22 dwg, 34 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF COAGULATION DISORDERS BY ADMINISTRATION OF RECOMBINANT WILLEBRAND FACTOR | 2019 |
|
RU2787855C2 |
| TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT vWF | 2012 |
|
RU2628537C2 |
| CONJUGATES OF BLOOD COAGULATION PROTEINS | 2010 |
|
RU2595442C2 |
| BLOOD COAGULATION PROTEIN CONJUGATES | 2010 |
|
RU2744370C2 |
| TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING PLANNED SURGICAL INTERVENTION BY ADMINISTRATION OF RECOMBINANT VWF | 2018 |
|
RU2766118C2 |
| METHOD OF PREPARING THE STANDARDIZED CONCENTRATION OF HUMAN VILLEBRAND FACTOR AND CONCENTRATE OBTAINED BY THIS METHOD | 1992 |
|
RU2088590C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
| PRODUCING PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES INDUCING DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND USE THEREOF IN THERAPY OF GD2-POSITIVE TUMORS | 2017 |
|
RU2663104C1 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
